Retrieved from Pfizer
The interim results from an ongoing phase 3 trial show their vaccine candidate presents a 90% efficacy preventing symptomatic COVID-19 infection. But it’s hard to imagine having mass distribution in countries with severe energy deficits . By Juan Carlos Gabaldón. Full Text -> CatacasChronicles
More Stories
Los retos que tendrá el próximo presidente de Venezuela
Biden’s New Order to Halt Asylum at the US Border
How to get Venezuela out of its cycle of conflict.